Market Pulse LIVECAST Terminal Brief Politics Macro Calendar

More

Stocks About Why SquawkNews Newsroom Schedule Prediction Markets Disclosure Wire Crypto Search

Market Pulse LIVECAST

Menu

Home Market Pulse LIVECAST Terminal Brief Politics Macro Calendar Stocks About Why SquawkNews Newsroom Schedule Prediction Markets Disclosure Wire Crypto Search

Live News EQUITY L impact Jul 14, 2026, 12:24 PM UTC

EOSE Initiate with a Buy, $7 PT @ Truist

EOSE Initiate with a Buy, $7 PT @ Truist

SquawkNews Newsroom

EOSE Initiate with a Buy, $7 PT @ Truist

Use this page

Share or save this market-moving headline as a permanent SquawkNews URL. The live feed continues at /news.

Open live news feed Browse news archive Browse news categories Search related coverage

Related tickers

EOSE

Related stories

JBHT CHRW RXO KNX Q226 Trucking/Logistics preview - positive KNX CHRW JBHT - promising pricing power @ SUSQ JBHT CHRW RXO KNX Q226 Trucking/Logistics preview - positive KNX CHRW JBHT - promising pricing power @ SUSQ L impact | EQUITY | Jul 14, 2026, 01:20 PM UTC HONA Tat technologies Ltd: expands strategic relationship with Honeywell Aerospace - Under expansion, Co to become sole global authorized di HONA Tat technologies Ltd: expands strategic relationship with Honeywell Aerospace - Under expansion, Co to become sole global authorized distributor of spare Parts for 331-200/250 L impact | EQUITY | Jul 14, 2026, 01:18 PM UTC CSX upgraded to positive and downgraded CNI to Neutral while remain positive on CP and positive on UNP/NSC longer-term in railroads @ SUSQ CSX upgraded to positive and downgraded CNI to Neutral while remain positive on CP and positive on UNP/NSC longer-term in railroads @ SUSQ L impact | EQUITY | Jul 14, 2026, 01:16 PM UTC BE Buyers on Weakness, Reiterate Outperform W/ $335 PT @ RBC BE Buyers on Weakness, Reiterate Outperform W/ $335 PT @ RBC L impact | EQUITY | Jul 14, 2026, 01:16 PM UTC BIIB Biogen presents phase 2 celia data at aaic demonstrating meaningful clinical outcomes and robust Tau reduction with diranersen in early BIIB Biogen presents phase 2 celia data at aaic demonstrating meaningful clinical outcomes and robust Tau reduction with diranersen in early alzheimer’s disease Biogen - to advance L impact | EQUITY | Jul 14, 2026, 01:15 PM UTC ASML PT raised from $1,700 to $2,000, maintains Outperform @ RBC ASML PT raised from $1,700 to $2,000, maintains Outperform @ RBC L impact | EQUITY | Jul 14, 2026, 01:15 PM UTC

SQUAWK/NEWS

Real-time financial news agency. Market-moving headlines, macro, politics, filings and audio squawk built for traders.

Product

LiveCast
Terminal
Brief
Macro
Calendar
Search

Company

About
Why SquawkNews
Newsroom
Editorial Standards
Corrections
Contact

© 2026 SquawkNews robots / sitemap SquawkNews publishes factual market information and context. It is not investment advice and does not provide trade recommendations.